- Home
- NEPH vs LSTA Comparison
NEPH vs LSTA Comparison
Compare NEPH & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEPH
- LSTA
- Stock Information
- Founded
- NEPH 1997
- LSTA 1980
- Country
- NEPH United States
- LSTA United States
- Employees
- NEPH N/A
- LSTA N/A
- Industry
- NEPH Medical/Dental Instruments
- LSTA Misc Health and Biotechnology Services
- Sector
- NEPH Health Care
- LSTA Health Care
- Exchange
- NEPH Nasdaq
- LSTA Nasdaq
- Market Cap
- NEPH 16.8M
- LSTA 20.0M
- IPO Year
- NEPH 2004
- LSTA N/A
- Fundamental
- Price
- NEPH $2.13
- LSTA $2.10
- Analyst Decision
- NEPH Buy
- LSTA Strong Buy
- Analyst Count
- NEPH 1
- LSTA 1
- Target Price
- NEPH $5.00
- LSTA $15.00
- AVG Volume (30 Days)
- NEPH 12.4K
- LSTA 10.4K
- Earning Date
- NEPH 05-08-2025
- LSTA 05-08-2025
- Dividend Yield
- NEPH N/A
- LSTA N/A
- EPS Growth
- NEPH N/A
- LSTA N/A
- EPS
- NEPH 0.01
- LSTA N/A
- Revenue
- NEPH $14,162,000.00
- LSTA $1,000,000.00
- Revenue This Year
- NEPH $9.23
- LSTA N/A
- Revenue Next Year
- NEPH $12.99
- LSTA N/A
- P/E Ratio
- NEPH $298.53
- LSTA N/A
- Revenue Growth
- NEPH N/A
- LSTA N/A
- 52 Week Low
- NEPH $1.36
- LSTA $2.05
- 52 Week High
- NEPH $2.55
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- NEPH 78.82
- LSTA 36.84
- Support Level
- NEPH $1.55
- LSTA $2.07
- Resistance Level
- NEPH $1.62
- LSTA $2.46
- Average True Range (ATR)
- NEPH 0.10
- LSTA 0.16
- MACD
- NEPH 0.06
- LSTA -0.01
- Stochastic Oscillator
- NEPH 87.79
- LSTA 6.25
About NEPH Nephros Inc.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.